Scientists at Scripps Research have edged closer to achieving a victory over HIV research with a new vaccine strategy that would predict engineered immune cells from the patient's body. Scientists interested in seeking the cure to the virus that threatens to kill millions around the world have come far closer to achieving an answer to the Holy Grail that would make HIV vaccine development feasible. According to the study, HIV is a disease that has proved difficult to avoid with traditional antibodies, as it progresses rapidly in the body. A solution to the same will involve constant persuasion of the body to develop a special form of antibody, according to the researchers, which can work widely to defeat several strains of the virus at once. This study has inspired scientists to work on an approach that would focus on the patient's body's genetically modified immune cells. The new study says that after being reintroduced into the body, engineered B cells multiply in response to vaccination and develop into memory and plasma that will produce high levels of defensive antibodies in the body for a long period of time. In general terms, all vaccines work the same way: if they appear in the body in the future, they prime the immune system to recognize and attack a particular pathogen. This can be achieved in a number of ways: by inactivating or weakening the pathogen, using only part of it or combining it with something else that makes it provoke an immune response, you can produce a vaccine. Our journals main aim is to draws readers' attention to the latest advances in HIV research in the fields of prevention, care and cure. The peoples who are interested to publish their article they can submit their manuscripts in our journal through given link: https://www.scholarscentral.org/submissions/hiv-aids-research.html